Brief: Q32 Bio Provides Bempikibart Program Update, Including Next Steps For Advancing Alopecia Areata Development Program

Q32 Bio

10/12/2024 22:39

Dec 10 (Reuters) - Q32 Bio Inc  QTTB.O :
    * Q32 BIO PROVIDES BEMPIKIBART PROGRAM UPDATE, INCLUDING
NEXT
STEPS FOR ADVANCING ALOPECIA AREATA DEVELOPMENT PROGRAM
    * Q32 BIO : SIGNAL-AD PHASE 2A CLINICAL TRIAL IN ATOPIC
DERMATITIS
DEMONSTRATED PROMISING FINDINGS IN PART A BUT DID NOT MEET
PRIMARY ENDPOINT IN PART B
    * Q32 BIO INC: ACROSS BOTH TRIALS, BEMPIKIBART WAS OBSERVED
TO BE
SAFE AND WELL TOLERATED
    * Q32 BIO : PLANS TO EXPAND SIGNAL-AA PHASE 2A CLINICAL
TRIAL AND
ENROLL ADDITIONAL PATIENTS EVALUATING BEMPIKIBART IN AA

Source text:  urn:newsml:reuters.com:*:nPn6kwdzla
Further company coverage:  QTTB.O 

 ((Reuters.Briefs@thomsonreuters.com;))